08:30 AM EDT, 03/18/2025 (MT Newswires) -- Ocugen ( OCGN ) said Tuesday that an independent safety board reviewed data from the first dosing group in its phase 1 trial of OCU200 for diabetic macular edema and approved advancing to the second group.

The company said the trial is testing OCU200, a fusion protein combining two human proteins, in patients receiving two doses six weeks apart.

Ocugen ( OCGN ) said it plans to complete the study in H2 and provide periodic updates on safety and efficacy.